TABLE 1.
Characteristics of all included patients
| Site | All (n=195) | p-value | |||
| LUMC (n=120) | HMC-W (n=60) | AL (n=15) | |||
| Age (years) | 49.5±18.7 | 51.6±18.1 | 53.2±20.2 | 50.4±18.6 | 0.649 |
| Male | 61/120 (50.8) | 28/60 (46.7) | 9/15 (60.0) | 98/195 (50.3) | 0.639 |
| Originating from TB endemic region# | 35/117 (29.9) | 23/60 (38.3) | 3/15 (20.0) | 61/192 (31.8) | 0.343 |
| Reason for testing | 0.018 | ||||
| Suspect for active TB | 36/120 (30.0) | 29/60 (48.3) | 8/15 (53.3) | 73/195 (37.4) | |
| Screening for TB infection | 84/120 (70.0) | 31/60 (51.7) | 7/15 (46.7) | 122/195 (62.6) | |
| Immunosuppression/pre-transplantation | 40/84 (47.6) | 22/31 (71.0) | 5/7 (71.4) | 67/122 (54.9) | |
| Screening donor | 7/84 (8.3) | 0/31 (0) | 0/7 (0) | 7/122 (5.7) | |
| Contact investigation | 19/84 (22.6) | 3/31 (9.7) | 0/7 (0) | 22/122 (18.0) | |
| Screening healthcare worker | 9/84 (10.7) | 1/31 (3.2) | 0/7 (0) | 10/122 (8.2) | |
| Other | 9/84 (10.7) | 5/31 (16.1) | 2/7 (28.6) | 16/122 (13.1) | |
| Immunosuppressive therapy ¶ | 22/89 (24.7) | 11/56 (19.6) | 0/14 (0) | 33/126 (20.8) | 0.129 |
| Biologicals | 1/22 (4.5) | 0/11 (0) | 0/14 (0) | 1/33 (3.0) | 1.000 |
| Calcineurin inhibitors | 2/22 (9.1) | 0/11 (0) | 0/14 (0) | 2/33 (6.1) | 0.542 |
| Anti-metabolites | 5/22 (22.7) | 1/11 (9.1) | 0/14 (0) | 6/33 (18.2) | 0.637 |
| Glucocorticoids | 13/22 (65.0) | 7/11 (63.6) | 0/14 (0) | 20/33 (60.6) | 1.000 |
| DMARDs | 5/22 (22.7) | 4/11 (36.4) | 0/14 (0) | 9/33 (27.3) | 0.438 |
| QFT | <0.001 | ||||
| <0.15 IU·mL−1 | 29/120 (24.2) | 18/60 (30.0) | 10/15 (66.7) | 57/210 (29.2) | |
| ≥0.15 and <0.35 IU·mL−1 | 65/120 (54.2) | 21/60 (35.0) | 1/15 (6.7) | 87/210 (44.6) | |
| ≥0.35 IU·mL−1 | 26/120 (21.7) | 21/60 (35.0) | 4/15 (26.7) | 51/210 (26.2) | |
Data are presented as mean±sd or n/N (%), unless otherwise stated. LUMC: Leiden University Medical Centre; HMC: Haaglanden Medical Centre Westeinde; AL: Alrijne Hospital Leiderdorp; TB: tuberculosis; DMARD: disease-modifying anti-rheumatic drug; QFT: QuantiFERON-TB Gold Plus. #: defined as a country with a TB incidence ≥40 cases of active TB per 100 000 inhabitants; ¶: only includes individuals from whom type and dose of immunosuppressive therapy could be retrieved.